AI Article Synopsis
- This study introduced a new nanomaterial, Mil-88a nanozyme, aimed at treating osteoarthritis (OA) in a mouse model.
- The researchers tested the safety of Mil-88a using CCK-8 assays and live-dead staining before constructing an OA model to examine its effects.
- Results showed that Mil-88a promotes OA-related anabolic gene expression and inhibits catabolic gene expression, leading to improved OA scores, suggesting its potential as a treatment strategy.
Article Abstract
In this paper we tried to conduct a novel nanomaterial strategy to overcome osteoarthritis (OA) in a mouse model. In this regard, after synthesizing the Mil-88a nanozyme, as a certain Fe-MOF, its toxic effects were detected by CCK-8 method and live-dead staining. The OA model of mouse was constructed, and paraffin sections of joints were taken for histological evaluation. In addition, immunofluorescence and immunohistochemistry were used to identify the OA progression and OARSI was used to evaluate the OA grades. We observed that Mil-88a could be easily synthesized and has high biocompatibility. We observed that Mil-88a could significantly promote the expression of OA anabolism-related genes such as and also significantly inhibit the expression of OA catabolism-related genes . Besides, we observed better OARSI score in animals treated with Mil-88a nano-enzyme loading on organic metal matrix. Overall, Mil-88a nano-enzyme could be used as a novel strategy to treat OA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175628 | PMC |
| http://dx.doi.org/10.3389/fbioe.2023.1164942 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!